Search for: "Novartis Pharmaceuticals Corporation" Results 81 - 100 of 146
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
18 Apr 2011, 5:51 pm by FDABlog HPM
Prior to joining HP&M, Linda served in several pharmaceutical industry positions, including as Senior Director, Global Regulatory Policy and Intelligence, Janssen Pharmaceutical Companies of Johnson & Johnson, Executive Director, FDA Liaison, Drug Regulatory Affairs, Novartis Pharmaceuticals Corporation, and Director, Global Regulatory Affairs, Legislative Policy and Regulatory Liaison, Pharmacia Corporation.  [read post]
9 Jan 2012, 4:00 am by Steve McConnell
Novartis Pharmaceuticals Corporation, Case No. 2:08-CV-02088 (W.D. [read post]
21 Nov 2017, 2:40 pm by Tom Lamb
We recommend that the FDA and [Novartis Pharmaceuticals Corporation] the manufacturer [of Entresto] more clearly communicate the full risk of hypotension, including appropriate steps for monitoring patients, and examine whether a more gradual escalation of dose to the recommended level would reduce the risk. [read post]
20 Oct 2007, 1:01 pm
It's Novartis AG v IVAX Pharmaceuticals UK Ltd [2007] EWCA Civ 971, in which the three-man appellate tribunal (Lords Justices Buxton, Jacob and Hughes) dismissed an appeal against the decision of Mr Justice Pumfrey that Novartis' patent for a pharmaceutical composition for an active ingredient, an 'oil-in-water microemulsion', was not infringed by the Ivax Equoral product in which at least 86% of the active ingredient was carried by particles… [read post]
10 Feb 2013, 4:00 pm by Amber Walsh
Astellas Venture Management is the corporate venture capital arm of Northbrook, Ill. [read post]
3 Aug 2013, 6:35 am by Anubha Sinha
Other significant suppliers are Ranbaxy Labs, Hetero Labs, Aurobindo Pharma, Haffkine Bio-Pharmaceutical Corporation, Biological E and Micro Labs Pharma. [read post]
24 Jan 2012, 6:34 pm by FDABlog HPM
District Court for the Northern District of Illinois (Eastern Division), the court denied Plaintiffs’ Seattle Children’s Hospital, Novartis Vaccines and Diagnostics, Inc., and Novartis Pharmaceuticals Corporation (collectively “Novartis”) Motion to Dismiss the lawsuit that they brought against Akorn, Inc. [read post]
2 Feb 2009, 9:51 am
This January 2008 press release from KV Pharmaceutical, the parent company of ETHEX, includes a list of the more than 60 generic drugs being recalled by ETHEX. [read post]
31 Dec 2013, 11:41 pm by Mark Summerfield
  In the US, the Court of Appeals for the Federal Circuit completely failed to come to terms with patent-eligibility of software-implemented inventions in the case of CLS Bank v Alice Corporation which is, as a consequence, now on its way to the Supreme Court.Australia’s High Court confirmed the patent-eligibility of methods of medical treatment, and in particular of methods for treating conditions using known pharmaceutical substances that have not previously been known… [read post]
30 Oct 2017, 3:46 pm by Baum Hedlund
(formerly Questcor Pharmaceuticals Inc.) of California; Mallinckrodt PLC of Ireland; and United BioSource Corporation (UBC) of Delaware. [read post]
13 Dec 2012, 9:44 am by Rajiv Kr. Choudhry
Amarendra Samal 1880/MUM/2008 LINCOLN PHARMACEUTICALS LIMITED Refused Dr. [read post]
6 Dec 2013, 3:14 pm
Switzerland also has a long history of social equality, and many citizens were offended by cases like that of Daniel Vasella, the former chief executive of the pharmaceutical company Novartis, who this year demanded a $78 million severance package in return for a promise not to share his know-how with any competitors. [read post]
19 Jul 2010, 7:07 pm by Piper Hoffman
The latest example is Novartis, a pharmaceutical company, which settled a gender discrimination class action for up to $175 million last week. [read post]
18 Apr 2014, 11:00 am
Novartis Pharmaceuticals Corp., No. 13-15433, 2014 U.S. [read post]
11 Jul 2011, 4:47 pm by FDABlog HPM
Kudos to The RPM Report team, which took note of some statements made during a recent meeting of FDA’s Arthritis Drugs Advisory Committee to discuss Novartis Pharmaceuticals Corporation’s (“Novartis’”) supplemental Biologics License Application (“sBLA”) for ILARIS (canakinumab) for the treatment of gouty arthritis attacks in certain patients.  [read post]
26 Oct 2007, 2:03 am
Court of Appeal (Civil Division) Neil Martin Ltd v HM Revenue & Customs [2007] EWCA Civ 1041 (25 October 2007) Cadogan & Anor v Sportelli & Anor [2007] EWCA Civ 1042 (25 October 2007) Boudh v Bodh [2007] EWCA Civ 1019 (25 October 2007) AA (Somalia) v SSHD [2007] EWCA Civ 1040 (25 October 2007) Kohn v Wagschal & Ors [2007] EWCA Civ 1022 (24 October 2007) Poole & Ors v HM Treasury [2007] EWCA Civ 1021 (24 October 2007) Wright & Ors, R (on the… [read post]